Modality
Radioligand
MOA
ALKi
Target
KIF18A
Pathway
JAK/STAT
T2D
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
Mar 2018
→ Nov 2030
Phase 1Current
NCT08953427
2,353 pts·T2D
2018-03→2030-10·Not yet recruiting
NCT08649352
1,457 pts·T2D
2025-06→2030-11·Terminated
3,810 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-08-128mo agoEMA Filing· T2D
2030-10-244.6y awayPh2 Data· T2D
2030-11-254.7y awayPh2 Data· T2D
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Not yet…
P1/2
Termina…
Catalysts
EMA Filing
2025-08-12 · 8mo ago
T2D
Ph2 Data
2030-10-24 · 4.6y away
T2D
Ph2 Data
2030-11-25 · 4.7y away
T2D
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08953427 | Phase 1/2 | T2D | Not yet recr... | 2353 | OS |
| NCT08649352 | Phase 1/2 | T2D | Terminated | 1457 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| ALN-3284 | Alnylam | Phase 2/3 | CDK2 |